BSX.N Hits 20-Day Low Amid Acquisition News
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 19 Nov 25
Source: SeekingAlpha
Shares of BSX.N declined sharply today, hitting a 20-day low as investor sentiment turned cautious. The stock's recent technical breakdown signals increased bearish momentum, reflecting broader concerns in the medical products sector. This decline comes on the heels of La Mancha Investments' recent acquisition of over 10 million shares of Belo Sun Mining Corp, raising its stake to 19.1%. While La Mancha's intentions to continue acquiring shares may indicate confidence in Belo Sun, the overall market challenges, including cost inflation and regulatory uncertainties, are weighing heavily on investor confidence in related stocks like Boston Scientific.
Analyst Views on BSX
Wall Street analysts forecast BSX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BSX is 125.74 USD with a low forecast of 112.00 USD and a high forecast of 140.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
20 Buy
0 Hold
0 Sell
Strong Buy
Current: 93.790
Low
112.00
Averages
125.74
High
140.00
Current: 93.790
Low
112.00
Averages
125.74
High
140.00
About BSX
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
